Jefferies Group disclosed Uniqure NV (NASDAQ:QURE), scaling down its target to $8.00 earlier today
- Updated: November 28, 2016
Yesterday Uniqure NV (NASDAQ:QURE) traded -3.07% lower at $6.85. The company’s 50-day moving average is $7.17 and its 200-day moving average is $8.54. The last stock close price is down -22.26% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 200,623 shares of the stock were exchanged, down from an average trading volume of 226,691
Jefferies Group dropped the price target of Uniqure NV (NASDAQ:QURE) to $8.00 stating a potential upside of 0.17%.
Previously on Monday November 21, 2016, Jefferies Group reported about Uniqure NV (NASDAQ:QURE) lowered the target price from $28.00 to $8.00. At the time, this indicated a possible upside of 0.12%.
See Chart Below
Uniqure NV has a 52 week low of $6.41 and a 52 week high of $22.79 The company’s market cap is currently $0.
About Uniqure NV (NASDAQ:QURE)
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.